Qualigen Therapeutics (QLGN) - שווי החברה ברכישה מלאה

Qualigen Therapeutics (QLGN) develops diagnostics and antiviral drugs. This price chart on the GURU.Markets platform shows that Qualigen Therapeutics (QLGN) has an Enterprise Value of . Business growth relies on the automated processing of massive test arrays. However, the legacy FastPack system is losing profitability and fails to offset biotech R&D costs. Additionally, fierce competition and a liquidity shortage are exerting pressure until the company reaches its break-even point.

To select assets with a high margin of safety, it is critical to analyze the real business value, which combines market capitalization with net debt. The enterprise value indicator allows for an assessment of the full acquisition price of Qualigen Therapeutics (QLGN), which is particularly significant given its asset-light R&D model and critical dependence on external contractors, reflecting the actual cost of managing this infrastructure.